论文部分内容阅读
目的:通过对肿瘤组织突变型p53基因蛋白表达状态,与E1B缺陷型腺病毒(简称H101)治疗恶性肿瘤疗效关系的研究,来探讨H101基因治疗的作用机制。方法:应用免疫组织化学方法对36例H101治疗的晚期恶性肿瘤病例进行肿瘤组织突变型p53基因蛋白检测,分析肿瘤组织突变型p53基因蛋白表达与H101临床疗效的关系。结果:突变型p53基因蛋白总阳性表达率均为69·4%(25/36);36例应用H101治疗的患者总有效率为61·1%(22/36)。其中p53+患者有效率72·3%(18/25),而p53-患者有效率36·3%(4/11)。两者比较,差异有统计学意义(P<0·05)。结论:H101对突变型p53基因蛋白阳性表达恶性肿瘤患者疗效高于突变型p53基因蛋白阴性者。
OBJECTIVE: To investigate the relationship between the expression of mutant p53 gene in tumor tissues and the efficacy of E1B-deficient adenovirus (H101) in the treatment of malignant tumors to explore the mechanism of H101 gene therapy. Methods: Immunohistochemistry was used to detect the mutant p53 gene protein in 36 cases of H101-treated advanced malignant tumor. The relationship between the mutant p53 gene protein expression and clinical efficacy of H101 was analyzed. Results: The total positive rate of mutant p53 gene protein was 69.4% (25/36). The total effective rate of 61 cases treated with H101 was 61.1% (22/36). Among them, the rate of p53 + patients was 72.3% (18/25), while that of p53-patients was 36.3% (4/11). The difference between the two groups was statistically significant (P <0.05). Conclusion: H101 is more effective than mutant p53 gene protein in patients with positive mutant p53 protein.